INBX - NASDAQ

Inhibrx Biosciences, Inc.

INBX·NASDAQ

$91.47

-2.3%

HealthcareBiotechnology

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.34B

EPS-9.0400

P/E Ratio-10.12

Earnings Date08/12/2026

inbx

Net Cash Provided by Financing Activities

Last Annual Value

101.45M

3-Year CAGR

-27%

5-Year CAGR

-9%

10-Year CAGR

13%

Adjust for Inflation

Inhibrx Biosciences, Inc. Competitors Analysis of Net Cash Provided by Financing Activities

INBX · NASDAQ

Company	Net Cash Provided by Financing Activities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Inhibrx Biosciences, Inc. NASDAQ:INBX	101.45M	-20.5%	3.9%	13.4%
Enliven Therapeutics, Inc. NASDAQ:ELVN	218.87M	-2.2%	N/A	N/A
Relay Therapeutics, Inc. NASDAQ:RLAY	1.60M	-64.1%	-66.6%	N/A
Atai Beckley Inc. NASDAQ:ATAI	269.48M	N/A	-8.0%	N/A
Amylyx Pharmaceuticals, Inc. NASDAQ:AMLX	257.03M	317.1%	10.2%	N/A
ORIC Pharmaceuticals, Inc. NASDAQ:ORIC	247.66M	42.5%	38.2%	N/A
Sana Biotechnology, Inc. NASDAQ:SANA	128.73M	59.6%	-27.3%	N/A
Syndax Pharmaceuticals, Inc. NASDAQ:SNDX	13.68M	-62.7%	-35.1%	-12.9%
Nektar Therapeutics NASDAQ:NKTR	180.57M	1719.0%	37.9%	-1.2%

Inhibrx Biosciences, Inc. Fair Value Envelope

INBX · NASDAQ

Our analysis suggests that INBX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $91.47, this represents a potential HIDDEN relative to our calculated worth for Inhibrx Biosciences, Inc..

HIDDEN

Intrinsic Value

Current Price: $91.47

Related Guides

Blog Categories

Continue your INBX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.